H.R.4629 - Star Rating for Biosimilars Act116th Congress (2019-2020)
|Sponsor:||Rep. Tonko, Paul [D-NY-20] (Introduced 10/08/2019)|
|Committees:||House - Energy and Commerce; Ways and Means|
|Latest Action:||10/18/2019 Sponsor introductory remarks on measure. (CR H8232) (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: H.R.4629 — 116th Congress (2019-2020)All Information (Except Text)
Introduced in House (10/08/2019)
Star Rating for Biosimilars Act
This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management.
The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.